A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma

Update Il y a 4 ans
Reference: EUCTR2004-002054-55

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

• In patients with advanced myeloma to assess the efficacy of PXD101 treatment (as measured by response rate (CR, PR, MR, NC/SD, PD) using the response criteria of Bladé et al Br.J.Haematol. 1998, 102: 1115-23)).


Inclusion criteria

  • Patients in relapse from prior treatment, with histologically and otherwise verified diagnosis of multiple myeloma